Acadia Pharmaceuticals (ACAD) Income towards Parent Company (2010 - 2026)

Acadia Pharmaceuticals' Income towards Parent Company history runs 17 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 80.53% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $375.7 million (up 64.12% YoY), while the FY2025 annual figure was $391.0 million, up 72.66% from the prior year.
• Income towards Parent Company was $3.7 million for Q1 2026 at Acadia Pharmaceuticals, down from $273.6 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $273.6 million in Q4 2025 to a low of -$113.1 million in Q1 2022.
• Historically, Income towards Parent Company has averaged $20.2 million across 5 years, with a median of $16.6 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Income towards Parent Company slumped 139.74% in 2023, then surged 2822.13% in 2024.
• A 5-year view of Income towards Parent Company shows it stood at -$41.7 million in 2022, then surged by 209.8% to $45.8 million in 2023, then jumped by 214.15% to $143.8 million in 2024, then jumped by 90.3% to $273.6 million in 2025, then plunged by 98.65% to $3.7 million in 2026.
• The last three Income towards Parent Company figures came in at $3.7 million (Q1 2026), $273.6 million (Q4 2025), and $71.8 million (Q3 2025), per Business Quant data.